ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Posoleucel as Preemptive Therapy for BKV Infection in Kidney Transplant Recipients: Safety and Tolerability in a Phase 2 Trial

R. K. Wali1, M. Singh2, D. Wojciechowski3, M. J. Ansari4, B. Lonze5, V. Nair6, A. Sharma7, S. Knechtle8, F. Cardarelli9, A. Chandraker10

1Inova Transplant Center, Falls Church, VA, 2U. of Pittsburg Medical Center, Harrisburg, PA, 3UT Southwestern Medical Center, Dallas, TX, 4Northwestern U. Feinberg School of Medicine, Chicago, IL, 5NYU Langone Transplant Institute, New York, NY, 6Northwell Health, Manhasset, NY, 7U. of Pittsburgh Medical Center, Pittsburgh, PA, 8Duke U. School of Medicine, Durham, NC, 9AlloVir, Cambridge, MA, 10Brigham & Women's Hospital, Boston, MA

Meeting: 2022 American Transplant Congress

Abstract number: 387

Keywords: Infection, Kidney transplantation, Polyma virus, T cells

Topic: Clinical Science » Infection Disease » 26 - Kidney: Polyoma

Session Information

Session Name: Plenary Session 3

Session Type: Plenary

Date: Tuesday, June 7, 2022

Session Time: 8:25am-9:30am

 Presentation Time: 8:30am-8:45am

Location: Hynes Veterans Auditorium

*Purpose: Kidney transplant (KT) recipients with BK viremia are at risk for BK virus (BKV) nephropathy and graft loss. There are no approved therapies for BKV infection. Posoleucel (PSL) is an off-the-shelf, allogeneic multivirus-specific T cell therapy. In a phase 2 trial of PSL in hematopoietic cell transplant recipients, 100% (27/27) of those with BKV disease had a clinical response.

*Methods: We are conducting a phase 2 double-blind study of PSL in KT recipients with BK viremia (NCT04605484) in which patients are randomized 1:1:1 to receive PSL (Groups 1 and 2) or placebo (PBO) for 12 weeks. PSL is infused once a week for 3 weeks, then every 14 days (Group 1) or every 28 days (Group 2). The primary objective is safety and tolerability with a key secondary objective to assess changes in BK viremia in recipients of PSL vs PBO.

*Results: The table shows baseline characteristics and safety events to date in the first 12 patients: 75% were male, median age 58.5 years, median follow-up 85 (range 41-169) days. In these blinded data, there have been very few and only transient grade 1 treatment-related adverse events (AEs), and no graft-versus-host disease, cytokine release syndrome, graft rejection, discontinuations due to AEs, or de novo donor-specific antibodies. Kidney allograft function was stable with mean change in eGFR of -0.4 mL/min/1.73m2. Analyses of PSL’s effect on other immune and viral endpoints will be presented.

*Conclusions: In this ongoing trial—the first randomized, double-blind placebo-controlled therapeutic trial of virus-specific T cell therapy in KT recipients with BK viremia—PSL was safe and well tolerated, supporting its continued evaluation as a preemptive therapy in KT recipients at risk for BKV nephropathy.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Wali RK, Singh M, Wojciechowski D, Ansari MJ, Lonze B, Nair V, Sharma A, Knechtle S, Cardarelli F, Chandraker A. Posoleucel as Preemptive Therapy for BKV Infection in Kidney Transplant Recipients: Safety and Tolerability in a Phase 2 Trial [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/posoleucel-as-preemptive-therapy-for-bkv-infection-in-kidney-transplant-recipients-safety-and-tolerability-in-a-phase-2-trial/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences